IRIS UniCatt

Rocca, Bianca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.469
AS - Asia 5.330
EU - Europa 5.034
SA - Sud America 1.210
AF - Africa 170
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 6
Totale 18.253
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.286
SG - Singapore 2.476
DE - Germania 1.335
CN - Cina 1.190
BR - Brasile 976
SE - Svezia 795
IT - Italia 665
UA - Ucraina 521
VN - Vietnam 486
FR - Francia 479
IE - Irlanda 292
GB - Regno Unito 205
ID - Indonesia 196
FI - Finlandia 184
IN - India 170
HK - Hong Kong 159
RU - Federazione Russa 142
PL - Polonia 136
JP - Giappone 125
AR - Argentina 100
TR - Turchia 93
BD - Bangladesh 90
CA - Canada 80
IQ - Iraq 69
MX - Messico 63
ES - Italia 51
NL - Olanda 45
KR - Corea 38
ZA - Sudafrica 38
BE - Belgio 35
AT - Austria 31
AU - Australia 31
EC - Ecuador 31
PK - Pakistan 30
CO - Colombia 29
CZ - Repubblica Ceca 27
IR - Iran 27
SA - Arabia Saudita 27
CI - Costa d'Avorio 25
ET - Etiopia 21
VE - Venezuela 21
PH - Filippine 20
CH - Svizzera 18
CL - Cile 15
PE - Perù 15
DZ - Algeria 11
EG - Egitto 11
JO - Giordania 11
PY - Paraguay 11
TN - Tunisia 11
UZ - Uzbekistan 11
IL - Israele 10
MA - Marocco 10
MY - Malesia 10
KE - Kenya 9
NP - Nepal 9
GH - Ghana 8
OM - Oman 8
AE - Emirati Arabi Uniti 7
DO - Repubblica Dominicana 7
GR - Grecia 7
KZ - Kazakistan 7
LV - Lettonia 7
NG - Nigeria 7
NO - Norvegia 7
TW - Taiwan 7
UY - Uruguay 7
AZ - Azerbaigian 6
BG - Bulgaria 6
HN - Honduras 6
KW - Kuwait 6
MK - Macedonia 6
SN - Senegal 6
AL - Albania 5
BH - Bahrain 5
BO - Bolivia 5
CR - Costa Rica 5
JM - Giamaica 5
LT - Lituania 5
PT - Portogallo 5
RO - Romania 5
TT - Trinidad e Tobago 5
AO - Angola 4
BY - Bielorussia 4
DK - Danimarca 4
KG - Kirghizistan 4
MN - Mongolia 4
HU - Ungheria 3
LB - Libano 3
MT - Malta 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PA - Panama 3
QA - Qatar 3
RS - Serbia 3
SV - El Salvador 3
TJ - Tagikistan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BJ - Benin 2
Totale 18.219
Salva come PNG Salva come JPEG
Città #
Singapore 1.207
Ashburn 876
Chandler 659
San Jose 656
Dublin 284
Jacksonville 259
Beijing 247
San Mateo 225
Jakarta 170
Wilmington 164
Nanjing 154
Lauterbourg 148
Ho Chi Minh City 147
Hong Kong 142
Los Angeles 141
Rome 140
Hanoi 124
Warsaw 122
New York 121
Woodbridge 120
Milan 108
Ann Arbor 106
Tokyo 104
Hefei 102
Houston 101
St Louis 98
Boston 97
Munich 97
Lawrence 92
Cattolica 88
Chicago 71
Dearborn 71
Fairfield 70
Frankfurt am Main 70
Moscow 66
São Paulo 64
Seattle 61
Nürnberg 59
Redwood City 59
Dallas 55
Princeton 53
Izmir 48
Helsinki 47
Santa Clara 45
Buffalo 41
Nanchang 38
Tianjin 37
Nuremberg 35
Council Bluffs 34
Shenyang 33
The Dalles 33
Mountain View 32
Da Nang 30
Kent 29
Paris 29
Seoul 29
Brussels 27
Boardman 26
Turku 26
University Park 26
Abidjan 25
Hangzhou 25
Redmond 25
Shanghai 25
Zhengzhou 25
Brooklyn 24
Hebei 24
Hyderabad 24
Bremen 23
Amsterdam 22
Brasília 22
Brno 22
Detroit 22
Guangzhou 22
Kunming 22
London 22
Orem 22
Rio de Janeiro 22
Belo Horizonte 21
Haiphong 21
Pune 21
Baghdad 19
Dhaka 19
Johannesburg 19
Atlanta 18
Cambridge 18
Phoenix 18
Toronto 18
Augusta 17
Bareggio 17
Denver 17
Wayne 17
Federal 16
Hounslow 16
Marseille 16
Mexico 16
Montreal 16
Tobarra 16
Vienna 16
Busto Arsizio 15
Totale 9.248
Salva come PNG Salva come JPEG
Nome #
Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count 332
More, more, more: Reducing thrombosis in acute coronary syndromes beyond dual antiplatelet therapy-current data and future directions 282
Mean Platelet Volume, Platelet Distribution Width, and Platelet Count in Type 2 Diabetes Mellitus, Impaired Fasting Glucose, and Metabolic Syndrome: systematic review and meta-analysis 254
Association of congenital protein C deficiency and latent myeloproliferative disease as cause of splanchnic venous thrombosis in a 34-year-old woman 251
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 224
Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. 199
Obesity is associated with in vivo platelet activation and impaired responsiveness to once-daily, low-dose aspirin 197
Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study 195
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 193
Prolonged fasting promotes systemic inflammation and platelet activation in humans: a medically supervised, water-only fasting and refeeding study 180
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 177
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 171
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 171
Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis 168
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 168
Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice 167
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 163
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13. A new prothrombotic mechanism associated with oxidative stress 162
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 162
Effect of fibrinogen concentration on the velocity of platelet aggregation. 161
Increased thromboxane biosynthesis in essential thrombocythemia. 157
Pseudo-acquired vWD in essential thrombocythemia: the role of platelets 156
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 146
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 146
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer 144
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 144
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy 143
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia 141
Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases 137
Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study 134
Drug insight: aspirin resistance- fact or fashion 134
Determinants of the interindividual variability in response to antiplatelet drugs. 131
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 131
Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes 130
Aspirin: promise and resistance in the new millennium. 129
Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo" 128
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 128
Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation 126
Effect of very long-term storage and multiple freeze and thaw cycles on 11-dehydro-thromboxane-B2 and 8-iso-prostaglandin F2α, levels in human urine samples by validated enzyme immunoassays 125
LACK OF AN ASSOCIATION BETWEEN INHERITED THROMBOPHILIC RISK FACTORS AND IDIOPATIC SUDDEN SENSORINEURAL HEARING LOSS IN ITALIAN PATIENTS 125
Aspirin, stroke and drug-drug interactions 123
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 121
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythemia 121
Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study 120
Successful pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. 119
Fechtner syndrome: report of a third family and literature review 119
Another family with IGPS 118
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response 118
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia 118
Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases 117
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 117
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 117
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD 117
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 116
Inherited macrothrombocytopenia with distinctive platelet ultrastructural and functional features 114
Farmaci antipiastinici 114
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis 114
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 114
Homocysteinemia is inversely correlated with platelet count and inversely correlated with sE-and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase 113
Type 2 Diabetes, Obesity, and Aspirin Responsiveness* 113
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 113
Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia 113
The future of antiplatelet therapy in cardiovascular disease 112
Platelet progenitors: the hidden drug target 112
Stability of the thromboxane B2 biomarker of low-dose aspirin pharmacodynamics in human whole blood and in long-term stored serum samples 111
Identifying determinants of variability to tailor aspirin therapy 111
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 111
Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 111
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial 110
Role of prostacyclin in the cardiovascular response to thromboxane A2 110
Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector. 108
Eicosanoid biosynthesis and metabolism in myeloproliferative disorders 108
Effect of ketorolac, ketoprofen and nefopam on platelet function 107
Cyclooxygenases and prostaglandins: shaping up the immune response 106
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 105
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 105
Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects 104
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment 103
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 102
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease 102
Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation 101
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 101
Aspirin, 110 years later 100
Nonsteroidal antiinflammatory drugs: past, present and future 100
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 99
Aspirin and Other COX-1 Inhibitors 99
Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation 97
The linkage between binding of the C-terminal domain of hirudin and amidase activity in human alpha-thrombin 97
Stability of urinary thromboxane A2 metabolites and adaptation of the extraction method to small urine volume 97
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 97
Increased thromboxane metabolites excretion in liver cirrhosis. 96
Familial autoimmune myasthenia gravis with different pathogenetic antibodies 96
Antithrombotic therapy in diabetes: which, when, and for how long? 96
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial 95
Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation 95
Wiskott-Aldrich syndrome: report of an autosomal dominant variant 94
Farmaci Antipiastrinici 94
Measurement of Thromboxane Biosynthesis in Health and Disease 94
Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors 93
A case of coloboma in a newborn to a woman taking mycophenolate mofetil in pregnancy after kidney transplantation. 93
Totale 13.153
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.315
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.315
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021215 0 0 0 0 0 0 0 0 0 0 181 34
2021/20221.145 157 93 13 73 86 32 32 187 44 33 175 220
2022/20232.133 313 301 176 241 175 237 75 172 257 43 95 48
2023/20241.357 43 348 42 179 80 132 97 29 28 69 136 174
2024/20252.510 61 54 196 89 199 67 36 155 416 214 556 467
2025/20266.940 1.124 208 530 733 1.056 330 1.221 352 479 582 325 0
Totale 18.477